Bridging EGFR/TGF-β Signaling to Bypass Resistance to Immune Checkpoint Blockade.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40986506.
- Also identified by DOI 10.1158/1078-0432.CCR-25-2727.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although EGFR is a common target in squamous cancers, anti-EGFR monotherapies have shown modest success because of existing or acquired activation of other oncogenic pathways and tumor heterogeneity. A bifunctional fusion protein ficerafusp alfa in combination with pembrolizumab represents a potential solution to overcome resistance in early-phase clinical investigation. See related article by Hernando-Calvo et al., p. 4623.
Medical subject headings
- Immune Checkpoint Inhibitors
- Drug Resistance, Neoplasm
- Signal Transduction
- Transforming Growth Factor beta
- Neoplasms